ReviewAnnals of hematology2026
Multidisciplinary approach to managing GPRC5D-related adverse events in relapsed or refractory multiple myeloma patients.
Review in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D)-targeting bispecific antibody, represents a novel therapy for patients with relapsed/refractory multiple myeloma (RRMM). Despite its promising efficacy, talquetamab is associated with distinctive adverse events (AEs), such as oral (dysgeusia, dysphagia, dry mouth) and dermatologic AEs (rashes, other skin-related symptoms, nail toxicities). These recommendations aim to develop a multidisciplinary framework for managing GPRC5D-related AEs, tailored for a wide audience that includes hematologists, oncology nurses, dieticians, and patients. A comprehensive literature review was conducted to identify current evidence and guidelines on GPRC5D-related AEs. Clinical experience from 12 Belgian healthcare professionals (6 hematologists, 4 nurses, 2 dieticians) was integrated and discussed to inform the development of practical recommendations. Data were synthesized to develop practical recommendations for managing common talquetamab-related AEs. Key AEs included dysgeusia, dry mouth, dysphagia, skin toxicities, and nail toxicities. These AEs, though mostly low-grade, impacted patient quality of life and nutritional status. Management strategies focused on dose modifications, oral care, dermatologic support, and early dietician referral. Patient education and multidisciplinary collaboration were identified as essential components of optimal supportive care. This is the first expert consensus-based set of multidisciplinary recommendations in Belgium addressing GPRC5D-related AEs. It provides practical, role-specific recommendations to support talquetamab-treated patients, improve tolerability, and optimize treatment adherence and outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.